Baracle(®) vs Baraclude(®) for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety

BACKGROUND AND OBJECTIVE: Entecavir (ETV) is a standard of care for chronic hepatitis B (CHB). In a bioequivalence study, ETV from Dong-A ST (Baracle(®)) was found to have a pharmacokinetic profile equivalent to ETV from Bristol-Myers Squibb (BMS) (Baraclude(®)). The present study was conducted to e...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Drug Des Devel Ther
Autori principali: Kim, Do Young, Kim, Ju Hyun, Tak, Won Young, Yeon, Jong Eun, Lee, Joon Hyeok, Yoon, Jung Hwan, Lee, Youn Jae, Lee, Byung Seok, Han, Byung Hoon, Lee, Han Chu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2017
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5673034/
https://ncbi.nlm.nih.gov/pubmed/29184389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S149199
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi